Advances in Treatment and Management of Ovarian Cancer: Emerging Concepts and Practical Guidance
  • CME

In this CME-certified activity, Bradley J. Monk, MD, FACS, FACOG, reviews key data supporting treatment advances in ovarian cancer, including optimal chemotherapy, VEGF inhibition, PARP inhibition, and more.
Bradley J. Monk, MD, FACS, FACOG
Physicians: maximum of 2.75 AMA PRA Category 1 Credits
Released: September 1, 2017 Expiration: August 31, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate current evidence and best practice recommendations to individualize first-line therapy for patients with advanced ovarian cancer
  • Apply current evidence and best practice recommendations to optimize therapy after progression for patients with advanced ovarian cancer
  • Evaluate the rationale and available clinical data for promising investigational agents and combination regimens for treating patients with advanced ovarian cancer in clinical trial or upon approval

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
AstraZeneca
Genentech

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Bradley J. Monk, MD, FACS, FACOG

Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona

Bradley J. Monk, MD, FACS, FACOG, has disclosed that he has received consulting fees from Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Gradalis, ImmunoGen, Insys, Merck, Perthera, Pfizer, Precision Oncology, Roche/Genentech, and Tesaro; fees for non-CME/CE services from AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, and Tesaro; and funds for research support from Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Morphotek, and Tesaro.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Krista Marcello

Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Kristen M. Rosenthal, PhD

Managing Editor

Kristen M. Rosenthal, PhD, has no real or apparent conflicts of interest to report.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who provide care for patients with advanced ovarian cancer.

Goal

The goal of this activity is to enhance participants’ ability to apply the latest standards of care and expert perspectives in the treatment of patients with advanced ovarian cancer.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 01, 2017, through August 31, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: July 10, 2018 Expiration: July 9, 2019

Downloadable PDF with clinical insights, approved agents, and available assays for MSI-high/MMR-deficient colorectal cancer and other solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Released: June 13, 2018

Downloadable PDF covering genetic risk, therapies, and testing strategies for BRCA1/2 mutations in breast, ovarian, pancreatic, and prostate cancers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Released: June 13, 2018

Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.

Released: December 14, 2017

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?